Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment

The last ten years have been characterized by an enormous step forward in the therapy and management of patients with Cystic Fibrosis (CF), thanks to the development and combination of Cystic Fibrosis Transmembrane Receptor (CFTR) correctors and potentiators. Specifically, the last approved triple c...

Descripción completa

Detalles Bibliográficos
Autores principales: Carnovale, Vincenzo, Scialò, Filippo, Gelzo, Monica, Iacotucci, Paola, Amato, Felice, Zarrilli, Federica, Celardo, Assunta, Castaldo, Giuseppe, Corso, Gaetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735556/
https://www.ncbi.nlm.nih.gov/pubmed/36498475
http://dx.doi.org/10.3390/jcm11236900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735556/
https://www.ncbi.nlm.nih.gov/pubmed/36498475
http://dx.doi.org/10.3390/jcm11236900

Ejemplares similares